A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality

European Journal of Preventive Cardiology

Volumn 20, Issue 5, 2013, Pages 827-836

  Støvring, Henrik ^a   Harmsen, Charlotte G ^b   Wisløff, Torbjørn ^c   Jarbøl, Dorte E ^b   Nexøe, Jørgen ^b   Nielsen, Jesper B ^b   Kristiansen, Ivar S ^d  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Absolute risk reduction; cardiovascular mortality; competing risk model; prolongation of life; risk prediction

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; MATHEMATICAL ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SEX RATIO; SMOKING;

ABSOLUTE RISK REDUCTION; CARDIOVASCULAR MORTALITY; COMPETING RISK MODEL; PROLONGATION OF LIFE; RISK PREDICTION;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAUSE OF DEATH; CHOLESTEROL; CORONARY DISEASE; DECISION SUPPORT TECHNIQUES; DYSLIPIDEMIAS; EUROPE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, STATISTICAL; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SMOKING; TIME FACTORS;

EID: 84884125172     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312445425     Document Type: Article

References (26)

1. Statistics Denmark. Available at: http://www.statistikbanken.dk/ statbank5a/SelectVarVal/Define.asp?MainTable=FOD5&PLanguage=1&PXSId=0 (consulted March 2012).
2. Statistics Denmark. Available at: http://www.statistikbanken.dk/ statbank5a/SelectVarVal/Define.asp?MainTable=FOD207&PLanguage=0&PXSId=0 (consulted March 2012).
3. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007 ; 28 (19). 2375-2414
4. Chen L, Tonkin AM, Moon L, et al. Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (5). 562-570
5. Christensen B, Faergemann O, Heeboll-Nielsen NC, et al Prevention of ischaemic cardiovascular disease in general practice. A clinical guideline. [In Danish]. 3 rd edn. Copenhagen: The Danish College of General Practitioners, 2007. Copenhagen: The Danish College of General Practitioners ; 2007 :
6. Hense HW, Koesters E, Wellmann J, et al. Evaluation of a recalibrated Systematic Coronary Risk Evaluation cardiovascular risk chart: results from Systematic Coronary Risk Evaluation Germany. Eur J Cardiovasc Prev Rehabil. 2008 ; 15 (4). 409-415
7. Lindman AS, Selmer R, Tverdal A, et al. The SCORE risk model applied to recent population surveys in Norway compared to observed mortality in the general population. Eur J Cardiovasc Prev Rehabil. 2006 ; 13 (5). 731-737
8. Meland E, Ellekjaer H, Gjelsvik B, et al. Pharmacological prevention of cardiovascular diseases in general practice. [In Norwegian with English summary]. Tidsskr Nor Laegeforen. 2000 ; 120 (22). 2643-2647
9. Merry AH, Boer JM, Schouten LJ, et al. Risk prediction of incident coronary heart disease in the Netherlands: re-estimation and improvement of the SCORE risk function. Eur J Cardiovasc Prev Rehabil 2011 [Epub ahead of print].
10. Norheim OF, Gjelsvik B, Kjeldsen SE, et al National guidelines for individual primary prevention of cardiovascular disease. [In Norwegian]. Oslo: Norwegian Directorate of Health ; 2009 :
11. Thomsen T, Christensen B, Hildebrandt P, et al Clinical guidelines for prevention of cardiovascular disease in Denmark. [In Danish]. Copenhagen: Danish Society of Cardiology ; 2004 :
12. van Dis I, Kromhout D, Geleijnse JM, et al. Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (2). 244-249
13. Bang LE, Boysen G, Christensen B, et al Alterations in clinical guidelines for prevention of cardiovascular disease from 2003 to 2007. [In Danish]. Copenhagen: Danish Society of Cardiology ; 2009 :
14. Selmer R, Lindman AS, Tverdal A, et al. Model for estimation of cardiovascular risk in Norway. [In Norwegian with English summary]. Tidsskr Nor Laegeforen. 2008 ; 3: 286-290
15. Silventoinen K, Pankow J, Lindstrom J, et al. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil. 2005 ; 12 (5). 451-458
16. Christensen PM, Brosen K, Brixen K, et al. A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. Clin Ther. 2003 ; 25 (10). 2575-2585
17. Dahl R, Gyrd-Hansen D, Kristiansen IS, et al. Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey. BMC Med Inform Decis Mak. 2007 ; 7: 8-8
18. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 ; 24 (11). 987-1003
19. Kalbfleisch JD, Prentice RL The statistical analysis of failure time data. 2 nd edn. Hoboken, NJ: J Wiley, 2002. Hoboken, NJ: J Wiley ; 2002 :
20. Vollset SE, Tverdal A, Gjessing HK. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med. 2006 ; 144 (6). 381-389
21. Danish National Board of Health. Available at: http://www. sundhedsprofil2010.dk/Pages/Home.aspx [In Danish] (consulted January 2012).
22. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-1278
23. Halvorsen PA, Kristiansen IS. Decisions on drug therapies by numbers needed to treat: a randomized trial. Arch Intern Med. 2005 ; 165 (10). 1140-1146
24. Kristiansen IS, Gyrd-Hansen D, Nexoe J, et al. Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. J Clin Epidemiol. 2002 ; 55 (9). 888-892
25. Wisloff T, Halvorsen PA, Kristiansen IS. Number needed to treat (NNT) - misleading, misunderstood, misused? [In Norwegian with English summary]. Tidsskr Nor Laegeforen. 2004 ; 124 (15). 1926-1929
26. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, et al. Helping doctors and patients make sense of health statistics. Psychological Science in the Public Interest. 2007 ; 8 (2). 53-96